Semaglutide tablets Wegovy.
Michael Siluk | Universal Images Group | Getty Images
Novo Nordisk on Tuesday launched a multi-month subscription program for its Wegovy obesity drug products, which aims to guarantee lower, “predictable” monthly prices for cash-paying patients.
Eligible patients can choose between a three-, six- or 12-month subscription for the Wegovy injection or the two highest doses of the newly launched pill under the same brand name. Longer plans offer lower monthly prices, and the company expects people to save up to $1,200 per year on the injection and up to $600 per year on the pill, compared to paying for their individual dose each month, according to a Novo release.
Patients can expect to pay fixed monthly prices, even if they switch to different doses, the company said. The subscription program will be available starting Tuesday on several of Novo’s telehealth partners, including Ro, WeightWatchers and LifeMD. Sesame, Him and her and more should be added soon.
The first-of-its-kind offering is “an opportunity to help patients not only begin but continue their treatment and help them manage the ups and downs associated with certain pricing considerations” whether they are starting treatment or currently taking the drug, said Ed Cinca, Novo’s head of marketing and patient solutions.
The inability to stay on GLP-1 has been a long-standing problem due to factors such as difficulty accessing the medication and gastrointestinal side effects, with a 2025 study estimating that approximately 65% of obese patients discontinue treatment within a year.
Wegovy Subscription Prices and Estimated Savings
Injection Subscription Plans (doses of 0.25, 0.5, 1.7 and 2.4 milligrams)
- 3 months: $329 per month, saving $240 per year
- 6 months: $299 per month, savings of $600 per year
- 12 months: $249 per month, savings of $1,200 per year
Pill Subscription Plans (doses of 9 and 25 milligrams)
- 3 months: $289 per month, saving $120 per year
- 6 months: $269 per month, savings of $360 per year
- 12 months: $249 per month, savings of $600 per year
The new program also comes as Novo’s pill, which has enjoyed explosive success since its U.S. launch in January, is poised to face new competition from an upcoming oral GLP-1 from its main rival. Elie Lilly later this year. Lilly is currently the dominant player in the branded GLP-1 market in the United States, with an estimated 60% share, while Novo has approximately 39%.
The Wegovy pill has largely reached people who had never received GLP-1 injections before, making it crucial for Novo to attract as many new patients as possible before a competitor arrives.
With the launch of Novo Nordisk’s subscription plans, cash-paying patients can still pay $149 per month for the lower doses of the pill, which are 1.5 and 4 milligrams. But starting in September, the 4-milligram dose will cost $199 per month. Meanwhile, Wegovy’s recently approved 7.2-milligram dose will be added to the subscription program at a later date.
Cinca emphasized that patients can unsubscribe from the subscription while it is active if they no longer wish to enroll.
“We want to help patients identify a path that can help them feel comfortable treating [obesity] in the long term,” he added.
Cinca said Novo does not yet offer the program on its direct-to-consumer NovoCare Pharmacy, but added that there is “an opportunity to evaluate how that’s going and then grow it” through that platform over time.